Emgality sales 2023?

See the DrugPatentWatch profile for Emgality

Emgality (galcanezumab-gnlm) Sales Performance in 2023

For the full year 2023, Emgality, a medication used for migraine prevention, generated $571 million in net sales [1]. This figure represents a 3% increase compared to the previous year [1].

What drove Emgality's sales in 2023?

The growth in Emgality's sales was primarily driven by a 12% increase in prescription volume, which offset a 7% decrease in net price [1]. Eli Lilly and Company, the manufacturer, noted that new patient starts on Emgality increased by 8% year-over-year [1]. The company attributed the prescription volume growth to the drug's expanded access and marketing efforts [1].

How do Emgality's sales compare to previous years?

In 2022, Emgality achieved net sales of $556 million [1]. This indicates a consistent, albeit modest, upward trend in revenue for the drug over the past two years [1].

What is Emgality's patent and exclusivity status?

Information regarding specific patent expiry dates and exclusivity periods for Emgality can be found on DrugPatentWatch.com [2]. The patent landscape for pharmaceuticals is complex and can impact market competition and pricing [2].

What are the key indications for Emgality?

Emgality is approved for the preventive treatment of episodic migraine in adults and for the treatment of episodic cluster headache in adults [3].

What is the mechanism of action for Emgality?

Emgality is a calcitonin gene-related peptide (CGRP) antagonist [3]. It works by blocking the activity of CGRP, a molecule that plays a role in migraine and cluster headache pain [3].

Are there other CGRP antagonists on the market?

Yes, several other CGRP antagonists are available for migraine treatment, including Aimovig (erenumab-aooe), Ajovy (fremanezumab-vfrm), and Vyepti (eptinezumab-jjfm) [4]. These medications differ in their administration, dosing frequency, and specific approvals [4].

What are common side effects of Emgality?

Common side effects of Emgality include injection site reactions, dizziness, and constipation [3].

Sources:

[1] Eli Lilly and Company. (2024, February 6). Eli Lilly and Company Reports 2023 Fourth Quarter and Full-Year Results. https://investor.lilly.com/news-releases/news-release-details/eli-lilly-and-company-reports-2023-fourth-quarter-and-full-year-results
[2] DrugPatentWatch.com.
[3] U.S. Food and Drug Administration. (n.d.). Emgality (galcanezumab-gnlm). Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/emgality-galcanezumab-gnlm
[4] DrugPatentWatch.com.